FOUND: 7 | Mind Blowing Facts

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK · Sep 16, 2025

The Guardian view on Merck’s exit: Britain’s biopharma strategy stalls in the face of China’s rise

Editorial: The industry’s retreat from the UK reflects a deeper shift about how Beijing is rewriting the rules of innovation

The Guardian - UK · Sep 15, 2025

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.

Benzinga · Sep 15, 2025

FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer

On Wednesday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Koselugo (selumetinib) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), benign, nerve sheath tumors.

Benzinga · Sep 10, 2025

AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study

On Sunday, AstraZeneca Plc (AZN) released results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial in previously untreated patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletion or exon 21 L858R mutations.

Benzinga · Sep 8, 2025

AstraZeneca, Corning And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his final trade.

Benzinga · Sep 4, 2025

AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure

On Saturday, AstraZeneca Plc (NASDAQ:AZN) released full results from the ​BaxHTN Phase 3 trial evaluating ​baxdrostat. The company released the topline data in July.

Benzinga · Sep 2, 2025

New blood pressure pill ‘lowers risk of heart problems in 12 weeks’

IN FULL

The Independent UK · Aug 30, 2025

The new daily pill that lowers high blood pressure by ‘spectacular’ amounts

Baxdrostat, developed by AstraZeneca, could help 10 million people worldwide

The Independent UK · Aug 30, 2025

New daily pill offers hope for millions with hard to control high blood pressure

A phase III trial of Baxdrostat showed it significantly lowered blood pressure in patients whose levels remained high despite being on other drugs.

The Independent UK · Aug 30, 2025